|
시장보고서
상품코드
1890918
이뇨제 시장 : 약제 클래스별, 적응증별, 투여 경로별, 작용기서별, 연령층별, 제제 유형별, 유형별, 유통경로별, 최종사용자별, 지역Diuretics Drugs Market, By Drug Class, By Indication, By Route of Administration, By Mechanism of Action, By Age Group, By Formulation Type, By Type, By Distribution Channel, By End User, By Geography |
||||||
이뇨제 시장은 2025년에 283억 4,000만 달러로 추정되며, 2032년까지 415억 달러에 달할 것으로 예측됩니다. 2025-2032년 CAGR 5.6%로 성장할 전망입니다.
| 리포트 커버 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2024년 | 2025년 시장 규모 : | 283억 4,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2025-2032년 |
| 예측 기간인 2025-2032년의 CAGR : | 5.60% | 2032년 예측 : | 415억 달러 |
세계 이뇨제 시장은 제약 산업에서 중요한 부분을 차지하고 있으며, 소변의 생성을 촉진하고 체내의 과도한 수분과 나트륨 배출을 돕기 위해 특별히 고안된 약물을 포함하고 있습니다. 일반적으로 '물약'이라고도 불리는 이뇨제는 고혈압, 심부전, 부종, 신장질환 등 다양한 심혈관계 및 신장계 질환의 관리에 중요한 역할을 합니다.
이들 치료제는 주로 신장의 네프론을 표적으로 하여 나트륨 재흡수를 억제하고 결과적으로 체액 배출을 촉진하여 혈액량을 감소시키는 다른 작용기전으로 작용합니다. 시장은 티아지드계 및 티아지드 유사 이뇨제, 루프 이뇨제, 칼륨 유지성 이뇨제, 탄산탈수효소 억제제 등 다양한 카테고리로 구성되어 있으며, 각 카테고리는 특정 치료 목적과 환자군을 대상으로 하고 있습니다. 생활습관병 증가, 고령화, 심혈관 질환에 대한 인식이 높아짐에 따라 전 세계에서 이뇨제 수요가 지속적으로 증가하고 있습니다. 의료진들 사이에서도 고혈압 치료의 1차 선택약물로서 이뇨제의 중요성과 병용요법에서 필수적인 성분으로서의 역할이 인식되고 있으며, 선진국과 신흥 국가를 막론하고 시장 확대를 주도하고 있습니다.
시장 역학
세계 이뇨제 시장은 몇 가지 강력한 촉진요인에 의해 주도되고 있습니다. 그 중에서도 고혈압과 심혈관 질환의 유병률 증가가 주요 성장 요인으로 작용하고 있습니다. 이러한 질환은 전 세계에서 수백만 명에게 영향을 미치고 장기적인 약물 치료가 필요하며, 이뇨제가 1차 선택 약물로 사용되는 경우가 많습니다. 빠르게 고령화되는 세계 인구도 시장 확대에 크게 기여하고 있습니다. 노인들은 심혈관 질환이나 신장 질환에 걸리기 쉬워 이뇨제 치료가 필요한 경향이 강한 반면, 좌식 생활과 나트륨 함량이 높은 식습관의 확산으로 젊은 층의 고혈압 발생률도 증가하고 있습니다.
정부의 심혈관 질환 예방 및 관리 촉진 정책과 신흥 시장의 헬스케어 인프라 확충이 맞물려 시장 성장을 더욱 가속화시키고 있습니다. 또한 이뇨제의 비용 효율성과 입증된 효과에 대한 의사들의 인식이 높아지면서 여러 동반 질환 관리에 있으며, 이뇨제의 비용 효과에 대한 인식이 높아지고 있습니다. 그러나 시장에는 눈에 띄는 제약도 존재합니다. 예를 들어 ACE 억제제, ARB(안지오텐신 수용체 차단제), 칼슘 채널 차단제 등 환자가 더 잘 견딜 수 있는 대체 강압제가 있다는 점, 이뇨제 사용에 따른 전해질 불균형, 특히 저나트륨혈증과 저칼륨혈증에 대한 우려는 처방의사의 신뢰와 환자의 복약 순응도를 제한할 수 있습니다. 처방의사의 신뢰와 환자의 복약 순응도를 제한할 수 있습니다. 또한 의약품 승인 과정의 엄격한 규제 요건과 탈수, 신장 기능 장애, 대사이상과 같은 잠재적 부작용이 시장 성장의 걸림돌로 작용하고 있으며, 이뇨제 단독 처방을 감소시킬 수 있는 병용요법에 대한 선호도가 높아짐에 따라 시장 성장에 어려움이 가중되고 있습니다.
본 조사의 주요 특징
- 이 보고서는 2024년을 기준 연도로 하여 예측 기간(2025-2032년) 시장 규모(10억 달러)와 예측 기간(2025-2032년)의 연평균 성장률(CAGR)을 나타내는 세계 이뇨제 시장에 대한 상세한 분석 정보를 제공합니다.
- 또한 각 부문의 잠재적 매출기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명합니다.
- 시장 성장 촉진요인, 제약요인, 기회, 신제품 출시 또는 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략에 대한 중요한 정보를 제공합니다.
- 이 보고서에서는 기업 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 세계 이뇨제 시장의 주요 기업 개요을 제공합니다.
- 이 보고서는 각 기업의 마케팅 담당자 및 경영진이 향후 제품 출시, 유형 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내리는 데 도움이 될 것입니다.
- 이 세계 이뇨제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 이뇨제 시장 분석에 사용된 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있습니다.
목차
제1장 조사 목적과 전제조건
- 조사 목적
- 전제조건
- 약어
제2장 시장 범위
- 리포트 개요
- 시장 정의와 범위
- 개요
제3장 시장 역학, 규제 및 동향 분석
- 시장 역학
- 촉진요인
- 억제요인
- 기회
- 영향 분석
- 주요 발전
- 규제 환경
- 제품 발매·승인
- PEST 분석
- Porter의 산업 분석
- 합병·인수의 동향
- 업계 동향
제4장 세계의 이뇨제 시장 : 약제 클래스별, 2020-2032년
- 치아지드계 이뇨제
- 루프 이뇨제
- 칼륨 유지성 이뇨제
- 탄산탈수소효소 저해제
- 침투압 이뇨제
- 기타 배합제
제5장 세계의 이뇨제 시장 : 적응증별, 2020-2032년
- 고혈압
- 녹내장
- 부종(예 : 심부전, 신장 기능 장애, 간경변)
- 특발성 두개내압 항진증
- 고산병
- 알도스테론증
제6장 세계의 이뇨제 시장 : 투여 경로별, 2020-2032년
- 경구
- 비경구
제7장 세계의 이뇨제 시장 : 작용기서별, 2020-2032년
- 나트륨-염화물모두 운송체 저해제
- 나트륨-칼륨-염화물모두 운송체 저해제
- 알도스테론 길항제
- 탄산탈수소효소 저해제
- 침투압 조절제
제8장 세계의 이뇨제 시장 : 연령층별, 2020-2032년
- 소아용
- 성인
- 고령자
제9장 세계의 이뇨제 시장 : 제제 유형별, 2020-2032년
- 정제/캡슐
- 경구 액제
- 주사제
제10장 세계의 이뇨제 시장 : 유형별, 2020-2032년
- 브랜드품
- 제네릭
제11장 세계의 이뇨제 시장 : 유통경로별, 2020-2032년
- 병원 약국
- 소매 약국
- 온라인 약국
제12장 세계의 이뇨제 시장 : 최종사용자별, 2020-2032년
- 병원
- 전문 클리닉
- 재택 의료 환경
- 연구기관·학술기관
제13장 세계의 이뇨제 시장 : 지역별, 2020-2032년
- 북미
- 미국
- 캐나다
- 라틴아메리카
- 브라질
- 아르헨티나
- 멕시코
- 기타 라틴아메리카 국가
- 유럽
- 독일
- 영국
- 스페인
- 프랑스
- 이탈리아
- 러시아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 한국
- ASEAN
- 기타 아시아태평양
- 중동
- GCC 국가
- 이스라엘
- 기타 중동 국가
- 아프리카
- 남아프리카공화국
- 북아프리카
- 중앙아프리카
제14장 경쟁 구도
- Pfizer Inc
- Novartis AG
- Sanofi
- Merck &Co Inc
- AstraZeneca PLC
- Johnson &Johnson
- Bayer AG
- Bristol-Myers Squibb Company
- Boehringer Ingelheim
- Teva Pharmaceutical Industries Ltd
- Mylan NV(now part of Viatris)
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Cipla Ltd
제15장 애널리스트의 권장사항
- 기회
- 애널리스트의 견해
- Coherent Opportunity Map
제16장 참고 문헌 및 조사 방법
- 참고 문헌
- 조사 방법
- 출판사 소개
Diuretics Drugs Market is estimated to be valued at USD 28.34 Bn in 2025 and is expected to reach USD 41.50 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.6% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 28.34 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 5.60% | 2032 Value Projection: | USD 41.50 Bn |
The global diuretics drugs market represents a critical segment within the pharmaceutical industry, encompassing medications specifically designed to increase urine production and facilitate the elimination of excess water and sodium from the body. Diuretics, commonly referred to as water pills, play an instrumental role in managing various cardiovascular and renal conditions, including hypertension, heart failure, edema, and kidney disorders.
These therapeutic agents function through different mechanisms, primarily targeting the kidneys' nephrons to inhibit sodium reabsorption, consequently promoting fluid elimination and reducing blood volume. The market comprises several distinct categories of diuretics, including thiazide and thiazide-like diuretics, loop diuretics, potassium-sparing diuretics, and carbonic anhydrase inhibitors, each serving specific therapeutic purposes and patient populations. The increasing prevalence of lifestyle-related diseases, aging demographics, and rising awareness of cardiovascular health have significantly contributed to the sustained demand for diuretic medications globally. Healthcare providers increasingly recognize the importance of diuretics as first-line treatments for hypertension management and as essential components in combination therapy regimens, driving market expansion across both developed and emerging economies.
Market Dynamics
The global diuretics drugs market is propelled by several compelling drivers, with the escalating prevalence of hypertension and cardiovascular diseases serving as the primary growth catalyst, as these conditions affect millions worldwide and require long-term pharmacological management where diuretics often represent first-line therapeutic interventions. The rapidly aging global population significantly contributes to market expansion, as elderly individuals demonstrate higher susceptibility to cardiovascular and renal disorders necessitating diuretic therapy, while simultaneously, the increasing adoption of sedentary lifestyles and dietary patterns high in sodium content have amplified the incidence of hypertension among younger demographics.
Government initiatives promoting cardiovascular disease prevention and management, coupled with expanding healthcare infrastructure in emerging markets, further accelerate the market growth, alongside growing physician awareness regarding the cost-effectiveness and proven efficacy of diuretic medications in managing multiple comorbid conditions. However, the market faces notable restraints including the availability of alternative antihypertensive medications such as ACE inhibitors, ARBs, and calcium channel blockers that may offer superior patient tolerance profiles, while concerns regarding electrolyte imbalances, particularly hyponatremia and hypokalemia associated with diuretic usage, may limit prescriber confidence and patient compliance. Additionally, stringent regulatory requirements for drug approval processes and potential adverse effects including dehydration, kidney dysfunction, and metabolic disturbances pose challenges to market growth, compounded by the increasing preference for combination therapies that may reduce standalone diuretic prescriptions.
Key Features of the Study
- This report provides in-depth analysis of the global diuretics drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global diuretics drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Pfizer Inc, Novartis AG, Sanofi, Merck & Co Inc, AstraZeneca PLC, Johnson & Johnson, Bayer AG, Bristol-Myers Squibb Company, Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd, Mylan NV (now part of Viatris), Hikma Pharmaceuticals PLC, Lupin Limited, Sun Pharmaceutical Industries Ltd, and Cipla Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global diuretics drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global diuretics drugs market
Market Segmentation
- Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
- Thiazide Diuretics (e.g., hydrochlorothiazide, chlorthalidone, indapamide, metolazone)<
- Loop Diuretics (e.g., furosemide, bumetanide, ethacrynic acid, torsemide)<
- Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene, eplerenone)<
- Carbonic Anhydrase Inhibitors (e.g., acetazolamide, methazolamide)<
- Osmotic Diuretics (e.g., mannitol)<
- Other Combination Products
- Indication Insights (Revenue, USD Bn, 2020 - 2032)
- Hypertension
- Glaucoma
- Edema (e.g., Heart Failure, Renal Impairment, Cirrhosis)
- Idiopathic Intracranial Hypertension
- Altitude Sickness
- Hyperaldosteronism
- Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Parenteral
- Mechanism of Action Insights (Revenue, USD Bn, 2020 - 2032)
- Sodium-Chloride Cotransporter Inhibitors
- Sodium-Potassium-Chloride Cotransporter Inhibitors
- Aldosterone Antagonists
- Carbonic Anhydrase Blockers
- Osmotic Pressure Regulators
- Age Group Insights (Revenue, USD Bn, 2020 - 2032)
- Pediatric
- Adult
- Geriatric
- Formulation Type Insights (Revenue, USD Bn, 2020 - 2032)
- Tablets/Capsules
- Oral Solutions
- Injections
- Type Insights (Revenue, USD Bn, 2020 - 2032)
- Branded
- Generic
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Hospitals
- Specialty Clinics
- Homecare Settings
- Research and Academic Institutes
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc
- Novartis AG
- Sanofi
- Merck & Co Inc
- AstraZeneca PLC
- Johnson & Johnson
- Bayer AG
- Bristol-Myers Squibb Company
- Boehringer Ingelheim
- Teva Pharmaceutical Industries Ltd
- Mylan NV (now part of Viatris)
- Hikma Pharmaceuticals PLC
- Lupin Limited
- Sun Pharmaceutical Industries Ltd
- Cipla Ltd
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Diuretics Drugs Market, By Drug Class
- Global Diuretics Drugs Market, By Indication
- Global Diuretics Drugs Market, By Route of Administration
- Global Diuretics Drugs Market, By Mechanism of Action
- Global Diuretics Drugs Market, By Age Group
- Global Diuretics Drugs Market, By Formulation Type
- Global Diuretics Drugs Market, By Type
- Global Diuretics Drugs Market, By Distribution Channel
- Global Diuretics Drugs Market, By End User
- Global Diuretics Drugs Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Diuretics Drugs Market, By Drug Class, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Thiazide Diuretics (e.g., hydrochlorothiazide, chlorthalidone, indapamide, metolazone)<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Loop Diuretics (e.g., furosemide, bumetanide, ethacrynic acid, torsemide)<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Potassium-Sparing Diuretics (e.g., spironolactone, amiloride, triamterene, eplerenone)<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Carbonic Anhydrase Inhibitors (e.g., acetazolamide, methazolamide)<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Osmotic Diuretics (e.g., mannitol)<
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Combination Products
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Diuretics Drugs Market, By Indication, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Glaucoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Edema (e.g., Heart Failure, Renal Impairment, Cirrhosis)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Idiopathic Intracranial Hypertension
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Altitude Sickness
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hyperaldosteronism
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Diuretics Drugs Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Parenteral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Diuretics Drugs Market, By Mechanism of Action, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Sodium-Chloride Cotransporter Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Sodium-Potassium-Chloride Cotransporter Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Aldosterone Antagonists
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Carbonic Anhydrase Blockers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Osmotic Pressure Regulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Diuretics Drugs Market, By Age Group, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Diuretics Drugs Market, By Formulation Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Tablets/Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Oral Solutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Injections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
10. Global Diuretics Drugs Market, By Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
11. Global Diuretics Drugs Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
12. Global Diuretics Drugs Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Homecare Settings
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Research and Academic Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
13. Global Diuretics Drugs Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Indication, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Mechanism of Action, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
14. Competitive Landscape
- Pfizer Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co Inc
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV (now part of Viatris)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hikma Pharmaceuticals PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Lupin Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical Industries Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Cipla Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
15. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
16. References and Research Methodology
- References
- Research Methodology
- About us
